SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Iris Acquisition Corp II entered into a material definitive agreement on October 20, 2026, which appears to involve financing or debt creation as part of a potential business combination or acquisition activity typical for a SPAC.
View raw filing on EDGAR →Melco Macau, an indirect subsidiary of Melco International Development Limited, entered into a limited partnership agreement on 23 October 2026 to subscribe for interests in the Macao SAR Government Guidance Fund No. 2 with a capital commitment of MOP828.0 million (approximately HK$803.2 million), representing 9.2% of aggregate commitments. The announcement explicitly states this constitutes a "discloseable transaction" under Hong Kong Listing Rules Chapter 14 (highest applicable percentage ratio is 5% or more but less than 25%). While the investment is made to fulfill non-gaming investment obligations under the Concession Contract and is not expected to materially affect the Company's financial position, the transaction involves a material capital commitment to a government-sponsored fund and represents a strategic operational/investment decision by the Company.
View raw filing on EDGAR →This 6-K furnishes preliminary financial performance figures for Woori Financial Group Inc. for the third quarter ended September 30, 2026, presented on both a specified-quarter and cumulative basis with year-over-year comparisons. The disclosure includes consolidated revenue, operating income, income before tax, net income, and profit to equity holders for both the parent entity and its wholly-owned subsidiary Woori Bank. This is a periodic quarterly financial report, not a discrete earnings-release event, and should be deferred for separate processing as a periodic filing.
View raw filing on EDGAR →Autoliv issued a press release on October 23, 2026 announcing third-quarter 2026 financial results, including net sales of $2,693 million, operating margin of 9.4%, diluted EPS of $2.13, and full-year 2026 guidance, with detailed regional performance analysis and management commentary.
View raw filing on EDGAR →The 6-K discloses a board resolution on October 23, 2026 recommending a quarterly cash dividend of KRW 220 per common share, with a record date of November 10, 2026 and payout date of November 30, 2026. The total dividend amount is KRW 161.3 billion. This is a routine but material capital distribution to shareholders that would affect investor assessment of the registrant's capital allocation and shareholder returns.
View raw filing on EDGAR →Nam Tai Property Inc. announced the successful closing and full drawdown of a RMB 700 million, 15-year fixed-rate loan facility with Ping An Bank on October 16, 2026. The company used proceeds to refinance and repay an existing China CITIC Bank loan. This constitutes creation of a new direct financial obligation (debt issuance) under Item 2.03, with material terms disclosed including the 3.5% fixed annual interest rate, 15-year maturity, and 80-basis-point reduction from the prior loan rate. The transaction is material to investors as it affects the company's cost of capital, debt maturity profile, and financial flexibility.
View raw filing on EDGAR →MarketAxess Holdings reported Q3 2026 financial results ended September 30, 2026, with total revenues of $210.4 million (1% growth) and diluted EPS of $1.53 ($1.86 excluding notable items), along with detailed operational metrics across trading channels.
View raw filing on EDGAR →The company declared a regular quarterly dividend of $0.78 per share, payable on November 25, 2026 to stockholders of record as of November 11, 2026.
View raw filing on EDGAR →Tango announced updated Phase 1/2 clinical trial results for vopimetostat in combination with RAS(ON) inhibitors, demonstrating an 82% objective response rate and 88% 9-month progression-free survival in pancreatic cancer patients, with plans to initiate a Phase 3 registrational trial in the first half of 2027. The company also disclosed a strategic reprioritization approved by the Board to focus on PRMT5-targeted therapies and deprioritize novel target discovery, accompanied by a planned approximately 14% workforce reduction.
View raw filing on EDGAR →SLB Limited disclosed third-quarter 2026 financial results on October 23, 2026, reporting revenue of $9.45 billion, GAAP EPS of $0.49, net income of $735 million, and adjusted EBITDA of $2.07 billion, with comprehensive divisional, geographic, and year-over-year analysis.
View raw filing on EDGAR →ORIC Pharmaceuticals disclosed positive Phase 1b clinical trial data for enozertinib (ORIC-114) in EGFR atypical NSCLC patients, showing 84% systemic ORR and 70% CNS ORR with favorable safety profile, and announced plans to initiate a global Phase 3 registrational trial (Redwood-1) in the first half of 2027.
View raw filing on EDGAR →The filing discloses the appointment of Raj Seshadri to Fiserv's board of directors effective November 30, 2026, with detailed background on her qualifications and independence determination. While the section also mentions Henrique De Castro's decision not to stand for re-election, the principal disclosed action centers on the new director appointment. Board composition changes are material to investors assessing governance and strategic direction.
View raw filing on EDGAR →Lake Shore Bancorp's Board declared a cash dividend of $0.09 per share on October 21, 2026, payable November 11, 2026 to shareholders of record as of November 2, 2026. This is a straightforward dividend distribution to common shareholders, which is material to investors as it represents a return of capital and signals management's confidence in the company's financial position.
View raw filing on EDGAR →Rogers Communications announced a quarterly dividend declaration of 50 cents per share on both Class B Non-Voting and Class A Voting shares, payable January 5, 2027 to shareholders of record on December 8, 2026. This is a routine but material dividend distribution to shareholders, which affects investor returns and is a standard capital allocation disclosure.
View raw filing on EDGAR →Aardvark disclosed exploratory efficacy and safety data from its terminated Phase 3 HERO trial and open-label extension trial for ARD-101, along with the FDA's lifting of the clinical hold and plans to resume clinical activities in 2027. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company—the data disclosure, regulatory clearance, and path-forward announcement would affect a reasonable investor's assessment of the drug development program's viability. While the data are explicitly labeled "exploratory" due to early termination, the convergence of efficacy signals, safety profile, and regulatory progress constitute a significant operational development that does not fit neatly into the specific financial, governance, or legal categories.
View raw filing on EDGAR →CRH announced the completion of its $8.5 billion acquisition of Arcosa, Inc., a leading U.S. provider of aggregates and critical infrastructure products. The press release explicitly states "CRH completes $8.5B acquisition of Arcosa" and describes this as a material strategic transaction that "reinforces CRH's position as the leader in U.S. and global aggregates" and advances the company's growth strategy. This is a completed material acquisition requiring disclosure under Item 1.01 or 2.01 of Form 8-K.
View raw filing on EDGAR →Tempus announced a series of material commercial agreements with Bristol-Myers Squibb and Pathos AI totaling $192.5 million in aggregate cash payments over five years. The disclosure covers licensing of de-identified oncology and neurology data, software tools, and related services—a significant strategic partnership and revenue-generating arrangement. While this is a material operational and commercial event, it does not fit the specific categories of M&A activity, debt issuance, or other named financial events; it is best classified as a material operational/strategic business arrangement.
View raw filing on EDGAR →Walmart has entered into pricing agreements to issue approximately $3.0 billion in U.S. Notes and C$5.0 billion in Canadian Notes across multiple series with maturities ranging from 2029 to 2056. The disclosure details the principal amounts, interest rates, pricing, and net proceeds for each note series, constituting a material creation of new direct financial obligations under Item 8.01 (Other Events).
View raw filing on EDGAR →This is a straightforward earnings release disclosing Gorman-Rupp's third quarter and year-to-date 2026 financial results. The filing explicitly states "On October 23, 2026, The Gorman-Rupp Company issued a news release announcing its financial results for the third quarter ended September 30, 2026," with the full press release attached as Exhibit 99. The release reports record net sales of $193.3 million, record net income of $22.7 million ($0.86 per share), and record adjusted EBITDA of $41.8 million for Q3 2026, along with detailed year-to-date results and management commentary.
View raw filing on EDGAR →NovaBridge reports presentation of clinical trial data for ragistomig (ABL503/TJ-L14B), a bispecific antibody in Phase 1 development, at the ESMO Congress 2026. This is a material operational milestone for a bioscience company — clinical trial progress and data presentation at major medical conferences are significant events affecting investor assessment of pipeline advancement and competitive positioning. The disclosure does not fit a more specific category (not earnings, M&A, litigation, or governance), making operational_other appropriate.
View raw filing on EDGAR →Eikon disclosed clinical trial data for three drug candidates (EIK1003, EIK1004, EIK1005) presented at the 2026 ESMO Congress, including Phase 1/2 safety and efficacy results, objective response rates, adverse event profiles, and dose-escalation findings across multiple cohorts and combination strategies.
View raw filing on EDGAR →BV Financial issued a press release on October 23, 2026 announcing quarterly and nine-month financial results for the period ended September 30, 2026, including net income of $3.4 million ($0.42 per diluted share) for Q3 2026 and $8.0 million ($0.97 per diluted share) for the nine-month period. The press release, attached as Exhibit 99.1, contains comprehensive financial statements, performance ratios, and operational metrics typical of an earnings disclosure under Item 2.02.
View raw filing on EDGAR →The Company disclosed the sale of 16,740 Class D Common Shares for $462,000 under a continuous private placement offering of up to $2.165 billion in unregistered equity securities, conducted pursuant to Section 4(a)(2) and Regulation D Rule 506(c). This is a classic dilutive issuance of unregistered equity that would materially affect investor assessment of share dilution and capital structure.
View raw filing on EDGAR →Bolt Biotherapeutics completed its acquisition of Prana Therapies on October 23, 2026, via a stock-for-stock reverse merger in which Bolt issued 430,746 shares of common stock and 16,360.929 shares of Series D Preferred Stock (convertible into ~16.8M common shares) to Prana stockholders. The transaction fundamentally restructures Bolt's equity ownership (Prana holders own ~51.7% post-transaction) and pipeline, with Prana's lead program PRA-216 becoming Bolt's flagship asset, accompanied by a concurrent $120 million private placement financing.
View raw filing on EDGAR →Bolt completed an unregistered private placement of $120 million in Series D convertible preferred stock and warrants to purchase up to an additional $60 million, offered and sold in reliance on Section 4(a)(2) and Regulation D. Post-transaction, PIPE investors will own approximately 41.4% of common stock on a fully-diluted basis.
View raw filing on EDGAR →Dr. Sheila Gujrathi was appointed as Chief Strategy Officer and to the Board of Directors effective October 23, 2026, in connection with Bolt's acquisition of Prana Therapies.
View raw filing on EDGAR →Bolt disclosed Phase 1 clinical trial results for BDC-4182, a claudin 18.2-targeting antibody in gastric cancer, showing tolerability with mostly Grade 1/2 adverse events, no dose-limiting toxicities, and a 53% disease control rate in the every-2-weeks cohort.
View raw filing on EDGAR →Perspective Therapeutics announced updated interim Phase 1/2a clinical trial results for [212Pb]VMT-α-NET presented at ESMO Congress 2026, showing encouraging efficacy (33–50% ORR across cohorts), durable disease control (72% PFS at 18 months), and favorable safety profile (no dose-limiting toxicities, no treatment discontinuations). The company is advancing toward Phase 3 site preparation with expected initiation in 2027. This is a material clinical development milestone for a radiopharmaceutical company with a single lead program, affecting investor assessment of pipeline progress and regulatory pathway viability.
View raw filing on EDGAR →The filing discloses an unregistered sale of equity securities (common stock) pursuant to Item 3.02, with an aggregate offering price of $16.7 million. The shares are being issued under subscription agreements to existing investors via capital calls, exempt from Securities Act registration under Section 4(a)(2) and Regulation D. This is a classic dilutive issuance of unregistered equity to raise capital.
View raw filing on EDGAR →BancFirst Corporation completed the acquisition of Spirit BankCorp, Inc. and SpiritBank on October 22, 2026, with Spirit merged into BancFirst. The target bank has approximately $866.8 million in total assets and $776.4 million in deposits, representing a material acquisition that would affect a reasonable investor's assessment of the registrant's size, geographic footprint, and financial position.
View raw filing on EDGAR →Vista Credit Strategic Lending Corp. completed an unregistered sale of 371,804.601 shares of Class I common stock for $7.2 million to accredited investors and non-U.S. persons, relying on Section 4(a)(2) and Regulation D/S exemptions.
View raw filing on EDGAR →The Company disclosed preliminary net asset value (NAV) per share of $19.44 as of September 30, 2026, along with total investments of $2.2 billion and a debt-to-equity ratio of 0.97x, providing material financial metrics for investor assessment.
View raw filing on EDGAR →The filing discloses that a proposed domination and profit and loss transfer agreement (DPLTA) between Kloeckner and Worthington Steel's subsidiary failed to receive required shareholder approval at Kloeckner's extraordinary general meeting. While Worthington Steel retains its 62% majority stake in Kloeckner (acquired in June 2026) and continues consolidating Kloeckner's financials, the failure of the DPLTA represents a material setback to the company's stated long-term strategic rationale for the acquisition. This is a material event affecting the registrant's M&A strategy, though it does not fit neatly into the standard M&A taxonomy categories (which typically cover entry, completion, or termination of transactions rather than post-acquisition governance failures).
View raw filing on EDGAR →The filing discloses the Board of Directors' approval of a quarterly cash dividend of $0.90 per share on common stock, payable January 4, 2027 to shareholders of record as of November 13, 2026. This is a straightforward dividend declaration, which is a material event affecting shareholder value and capital allocation decisions.
View raw filing on EDGAR →EQT Private Equity Company LLC disclosed an unregistered sale of equity securities (663,060 shares across multiple classes) for approximately $19.1 million in aggregate consideration as of October 1, 2026. The offering was conducted under Section 4(a)(2) and Regulations D and S, which are classic exemptions for private placements. This is a textbook dilutive issuance under Item 3.02, and the cumulative $880+ million raised since inception demonstrates material capital-raising activity that would affect investor assessment of the company's capitalization and ownership structure.
View raw filing on EDGAR →EQT Infrastructure sold approximately $92.1 million in unregistered Investor Shares across multiple share classes to third-party investors as of October 1, 2026, relying on Section 4(a)(2) and Regulations D and S exemptions. This is a classic dilutive private placement of equity securities. The filing explicitly discloses this as part of a continuous private offering that has raised approximately $1.1 billion since inception in February 2026, making it material to investors' assessment of ownership dilution and capital structure.
View raw filing on EDGAR →The filing discloses both the departure of Peter Knag as CFO and the appointment of Andrew Pieper as Interim CFO, effective October 20, 2026. While both events occur, the appointment of a new CFO to assume "principal financial officer and principal accounting officer" roles is the forward-looking material action. The departure is characterized as amicable ("not the result of any disagreement") with transition support, making the appointment the more salient event for investors assessing leadership continuity.
View raw filing on EDGAR →The Company adopted an amended and restated Senior Officer Severance Plan on October 22, 2026, modifying compensatory arrangements for named executive officers including the CEO, CFO, and other senior officers. The amendments increased severance multipliers (CEO multiplier from 2.5x to 3x in change-of-control scenarios) and expanded cash severance calculations to include Target Bonus, representing material modifications to executive compensation and severance terms that would affect investor assessment of executive cost and retention risk.
View raw filing on EDGAR →Aptevo Therapeutics amended its Rights Agreement (Amendment No. 6), extending the Final Expiration Date to October 23, 2027 and adjusting the Purchase Price to $14.56 per Preferred Share. The amendment modifies security holders' rights under the shareholder rights plan.
View raw filing on EDGAR →Marvell entered into a Third Amended and Restated Revolving Credit Agreement on October 22, 2026, establishing a $3 billion revolving credit facility with an additional $2 billion in potential commitments. This represents the creation of a new direct financial obligation and material capital structure event, even though no borrowings were outstanding at the effective date. The facility replaces a prior $1.5 billion facility and includes customary financial covenants (leverage ratio of 4.00x), making it a material debt arrangement that would affect investor assessment of the company's liquidity and financial flexibility.
View raw filing on EDGAR →Black Mammoth Metals ceased to be a 'venture issuer' under NI 51-102 effective October 15, 2026, following its listing on the Nasdaq Capital Market. This regulatory status change materially affects the Corporation's continuous disclosure obligations and regulatory classification.
View raw filing on EDGAR →Black Mammoth Metals' common shares commenced trading on Nasdaq Capital Market under ticker 'BMMX' on October 15, 2026, following SEC approval of a Form 40-F registration statement, with simultaneous delisting from the OTC Pink Limited Market. This listing transfer represents a material strategic milestone enhancing the registrant's market access and visibility.
View raw filing on EDGAR →Jeremy Normington-Slay was appointed to the Boards of Directors of both Civista Bancshares and Civista Bank, effective October 21, 2026. This is a clear board appointment disclosed under Item 5.02, and the appointment of a director with significant executive leadership experience (President and CEO of Firelands Health) to a financial holding company's board is material to investors assessing governance and strategic direction.
View raw filing on EDGAR →The filing discloses the election of Chelsea Grayson as a Class II director to fill a vacancy created by the Board's increase from eight to nine directors on October 20, 2026. While the section also mentions Martin Taylor's prior resignation (December 19, 2025), the principal action disclosed in this 8-K is the appointment of a new director, making exec_appointment the most salient classification. The disclosure includes her term, independence status, and compensation arrangement ($40,000 monthly cash fee), all material to investors assessing board composition and governance.
View raw filing on EDGAR →First Eagle Private Credit Fund sold 416,844 unregistered Class I common shares for $9.8 million to a feeder vehicle, relying on Section 4(a)(2) and Regulation S exemptions from Securities Act registration.
View raw filing on EDGAR →The Fund declared regular distributions to shareholders of Class I and Class D common shares at $0.190 per share gross, with a record date of October 30, 2026 and payment date of November 27, 2026.
View raw filing on EDGAR →The Fund disclosed its Net Asset Value per share as of September 30, 2026 ($23.51 for both Class I and Class D), aggregate NAV of $292.2 million, portfolio weighted average yield of 9.73%, weighted average tenor of 3.651 years, and a debt-to-equity ratio of 0.90x.
View raw filing on EDGAR →The filing announces that Silvercrest will host a teleconference on October 30, 2026, to discuss "the Company's financial results for the third quarter ended September 30, 2026," with a news release containing results to be issued before market open. This is a standard earnings announcement disclosure, even though the actual results are not yet included in the 8-K itself—the announcement of the earnings call and the imminent release of Q3 2026 results constitutes an earnings_release event type.
View raw filing on EDGAR →This Item 8.01 disclosure centers on supplemental disclosures related to the pending merger between MarketAxess and Intercontinental Exchange, Inc. announced on July 29, 2026. The filing addresses litigation and stockholder demands challenging proxy statement disclosures, and provides additional detail on the merger background, negotiations, and process. While technically filed under Item 8.01 (Other Events), the substance is the company's response to challenges to a material acquisition transaction and the supplemental disclosures intended to support completion of the merger.
View raw filing on EDGAR →The filing discloses a special meeting called to vote on a "Business Combination pursuant to the Combination Agreement" involving an amendment to the Trust Indenture, with SoftVest and other unitholders holding >15% requesting the meeting. The Form S-4 filed by PBT Land and Minerals, Inc. and other participants (declared effective October 23, 2026) signals a material acquisition or change-of-control transaction requiring unitholder approval, making this a merger/combination activity disclosure under Item 8.01.
View raw filing on EDGAR →